Patents by Inventor Louis D. Heerze

Louis D. Heerze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of binding and removing toxin A
    Patent number: 5635606
    Abstract: This invention relates to treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC), using oligosaccharide compositions which bind C. difficile toxin A. More specifically, the invention concerns neutralization of C. difficile toxin A associated with CDAD.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: June 3, 1997
    Assignee: Synsorb, Biotech Inc.
    Inventors: Louis D. Heerze, Glen D. Armstrong
  • Treatment of traveller's diarrhea
    Patent number: 5627163
    Abstract: This invention relates to treatment of traveller's diarrhea, including diarrhea caused by enterotoxigenic Escherichia coli (ETEC) which treatment uses an oligosaccharide-containing composition. The composition contains an oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm. The oligosaccharide-containing composition binds E. coli heat-labile toxin (LT) and/or one or more serotypes of enterotoxigenic E. coli organisms. More specifically, the invention relates to prevention of ETEC from colonizing the intestinal tract and inducing disease. This invention also concerns neutralization and removal of LT associated with traveller's diarrhea.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 6, 1997
    Assignee: Synsorb Biotech, Inc.
    Inventors: Louis D. Heerze, Glen D. Armstrong
  • Treatment of antibiotic associated diarrhea
    Patent number: 5484773
    Abstract: This invention relates to treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC), using oligosaccharide compositions which bind C. difficile toxin A. More specifically, the invention concerns neutralization of C. difficile toxin A associated with CDAD.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: January 16, 1996
    Assignee: Alberta Research Council
    Inventors: Louis D. Heerze, Glen D. Armstrong
  • Lectin derived carbohydrate binding-peptide
    Patent number: 5453272
    Abstract: The invention is directed to a lectin derived carbohydrate binding-peptide which inhibits cell-mediated immune responses and has the amino acid sequence SPYGRC. The peptide binds terminally linked .alpha.-sialic acid (2.fwdarw.3).beta.Gal- and .alpha.-sialic (2.fwdarw.6).beta.Gal-structures and is a acid fragment of the S2 subunit of pertussis toxin produced by Bordetella pertussis.
    Type: Grant
    Filed: December 21, 1992
    Date of Patent: September 26, 1995
    Assignee: Alberta Research Council
    Inventors: Louis D. Heerze, Glen D. Armstrong, Richard Smith